Home  >  News
News
+ Font Resize -

Mylan introduces generic Estrace cream in US market

Hertfordshire, England
Tuesday, January 2, 2018, 17:00 Hrs  [IST]

Global pharmaceutical leader Mylan N.V has announced the US launch of estradiol vaginal cream USP, 0.01%, the first generic version of Allergan's Estrace cream. Mylan received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated in the treatment of vulvar and vaginal atrophy.

Mylan CEO Heather Bresch said, "The approval and launch of estradiol vaginal cream strengthens our robust women's healthcare portfolio and our commitment to helping women manage their health across every stage of their lives, from contraception and hormone replacement therapy to certain disorders that are highly prevalent in women, like hypothyroidism. Mylan is now one of only a few companies that will offer Estradiol as an option across four delivery systems – cream, gel, transdermal patch and tablet. This breadth allows us to deliver multiple options and, ultimately, greater value to customers, healthcare professionals and patients. Further, introducing a first-time generic demonstrates our leadership in continuing to create access to high quality medicine for patients and the US healthcare system."

Mylan president Rajiv Malik added, "Topicals like estradiol vaginal cream are a great example of Mylan's ability to bring to market complex products. We have made substantial investments in research and development of these difficult-to-develop medicines and believe this provides long-term sustainability for our business."

Estrogens increase the risk of endometrial cancer, and should not be used for the prevention of cardiovascular disease or dementia. Estrogen use is associated with an increased risk of stroke, DVT and dementia in postmenopausal women. Because of the risks associated with estrogen use, they should be prescribed at the lowest effective dose and for the shortest duration.

Estradiol vaginal cream USP, 0.01%, had US sales of approximately $449 million for the 12 months ending October 31, 2017, according to IQVIA.

Currently, Mylan has 211 ANDAs pending FDA approval representing approximately $93.4 billion in annual brand sales, according to IQVIA. Forty-six of these pending ANDAs are potential first-to-file opportunities, representing $42.1 billion in annual brand sales, for the 12 months ending July 31, 2017, according to IQVIA.

 

Post Your commentsPOST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
duphat_150x60
IPJPI18_150x60en_2018
PHARMACONNECT_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |